Dihydropelitinib
Dihydropelitinib (DHP) is a ILK ligand with a Kd value of 252 nM. Dihydropelitinib acts as a cytoskeleton modulator that induces actin (Actin) cytoskeleton rearrangement. Dihydropelitinib exhibits anticancer activity against liver cancer and lung adenocarcinoma. Dihydropelitinib can be used in studies related to liver cancer and lung adenocarcinoma.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C24H25ClFN5O2
- Masse moléculaire:469.94
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Dihydropelitinib (0.019-2.500 μM) binds specifically to the ILK:α-parvin complex, with an equilibrium dissociation constant (Kd) of 252 nM[1].
Dihydropelitinib (serial dilution; 2 h treatment) binds to full-length ILK in digitonin (HY-N4000)-permeabilized HEK293T cells, with an IC50 of 980 nM as determined by NanoBRET target binding assay[1].
Dihydropelitinib (0.22-2.50 μM; 48 h) induces concentration-dependent rearrangement of the actin cytoskeleton in hepatocellular carcinoma Huh-7 cells after 48 h of treatment[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
Masse moléculaire 469.94
-
Formule C24H25ClFN5O2
-
SMILES
FC(C=CC(NC1=C(C=NC2=CC(OCC)=C(NC(CCCN(C)C)=O)C=C12)C#N)=C3)=C3Cl
-
Synonyms
DHP
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)